ATE533060T1 - Assays mit pegylierten insulinähnlichen wachstumsfaktoren - Google Patents

Assays mit pegylierten insulinähnlichen wachstumsfaktoren

Info

Publication number
ATE533060T1
ATE533060T1 AT09726947T AT09726947T ATE533060T1 AT E533060 T1 ATE533060 T1 AT E533060T1 AT 09726947 T AT09726947 T AT 09726947T AT 09726947 T AT09726947 T AT 09726947T AT E533060 T1 ATE533060 T1 AT E533060T1
Authority
AT
Austria
Prior art keywords
assay
growth factors
insulin
pegylated insulin
growth
Prior art date
Application number
AT09726947T
Other languages
English (en)
Inventor
Kurt Lang
Andreas Schaubmar
Julia Schleypen
Tilman Schlothauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE533060T1 publication Critical patent/ATE533060T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT09726947T 2008-04-03 2009-03-31 Assays mit pegylierten insulinähnlichen wachstumsfaktoren ATE533060T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08006768 2008-04-03
PCT/EP2009/002319 WO2009121551A1 (en) 2008-04-03 2009-03-31 Pegylated insulin-like-growth-factor assay

Publications (1)

Publication Number Publication Date
ATE533060T1 true ATE533060T1 (de) 2011-11-15

Family

ID=39717834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09726947T ATE533060T1 (de) 2008-04-03 2009-03-31 Assays mit pegylierten insulinähnlichen wachstumsfaktoren

Country Status (13)

Country Link
US (2) US20110045510A1 (de)
EP (1) EP2274624B1 (de)
JP (1) JP5031923B2 (de)
KR (1) KR20100119899A (de)
CN (1) CN101965516A (de)
AT (1) ATE533060T1 (de)
AU (1) AU2009231186A1 (de)
BR (1) BRPI0911266A2 (de)
CA (1) CA2720478A1 (de)
ES (1) ES2375606T3 (de)
IL (1) IL207437A0 (de)
MX (1) MX2010010313A (de)
WO (1) WO2009121551A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893605T3 (es) * 2011-05-18 2022-02-09 Takeda Pharmaceuticals Co Ensayos de actividad dependientes de modificación
CN104718453B (zh) * 2012-10-03 2017-03-08 Gyros专利公司 酸性条件下分析物测定用方法和试剂盒
CN104697829B (zh) * 2015-02-10 2018-05-04 深圳市新产业生物医学工程股份有限公司 用于igf-ⅰ化学发光免疫检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
WO2017117236A1 (en) 2015-12-31 2017-07-06 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6235488B1 (en) * 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
EP0597033B1 (de) * 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1017794A1 (de) * 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptid-polymer-konjugate mit hinzugefügten oder entfernten bindungsgruppen
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US7067485B2 (en) * 1997-11-07 2006-06-27 Chiron Corporation IGF-I composition and its use
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6248546B1 (en) * 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
DE60042550D1 (de) * 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en) * 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
UA93662C2 (uk) * 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
WO2002094853A2 (en) * 2001-05-21 2002-11-28 Nektar Therapeutics Al, Corporation Antibodies specific for poly(ethylene glycol)
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
RU2010144014A (ru) * 2008-04-03 2012-05-27 Ф. Хоффманн-Ля Рош Аг (Ch) Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств

Also Published As

Publication number Publication date
EP2274624B1 (de) 2011-11-09
AU2009231186A1 (en) 2009-10-08
BRPI0911266A2 (pt) 2015-09-29
MX2010010313A (es) 2010-11-05
JP2011516843A (ja) 2011-05-26
EP2274624A1 (de) 2011-01-19
US20110045510A1 (en) 2011-02-24
CA2720478A1 (en) 2009-10-08
WO2009121551A1 (en) 2009-10-08
KR20100119899A (ko) 2010-11-11
JP5031923B2 (ja) 2012-09-26
IL207437A0 (en) 2010-12-30
ES2375606T3 (es) 2012-03-02
CN101965516A (zh) 2011-02-02
US20130089875A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
CU24058B1 (es) Antagonistas de pcsk9
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
EP2333116A3 (de) Marker für Nierentransplantatabstoßung und Nierenschäden
BR112016004437A2 (pt) métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
CR20120127A (es) Anticuerpos monoclonales
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
WO2008118970A3 (en) Constructs and libraries comprising antibody surrogate light chain sequences
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
EA201700111A1 (ru) Полипептидные конструкции и их применение
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
CR20110559A (es) Anticuerpos específicos para cadherina-17
DK2024747T3 (da) Anvendelse af protein SATB2 som prognotisk markør for colerectal cancer
MY172290A (en) Immunochromatography devices, methods, and, kits
MX372998B (es) Proteinas de captura de superficie celular recombinantes.
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
WO2010006286A3 (en) Constructs and libraries comprising antibody surrogate kappa light chain sequences
BR112012019475A2 (pt) "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
WO2010096674A3 (en) A+ biomarker assays
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
ATE533060T1 (de) Assays mit pegylierten insulinähnlichen wachstumsfaktoren
ZA201705365B (en) Homogenous immunoassay with compensation for background signal
WO2006076687A3 (en) Elisa assays using prion-specific peptide reagents
WO2014151290A3 (en) Assay for predictive biomarkers